Compare ELMT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMT | EDIT |
|---|---|---|
| Founded | 1929 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.9M | 422.3M |
| IPO Year | 2026 | 2016 |
| Metric | ELMT | EDIT |
|---|---|---|
| Price | $19.69 | $1.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $29.00 | $6.10 |
| AVG Volume (30 Days) | 472.3K | ★ 2.1M |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.50 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $31,937,000.00 |
| Revenue This Year | $34.89 | N/A |
| Revenue Next Year | $29.22 | N/A |
| P/E Ratio | $194.45 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $12.49 | $1.66 |
| 52 Week High | $25.46 | $3.94 |
| Indicator | ELMT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 30.69 |
| Support Level | $17.53 | N/A |
| Resistance Level | $21.38 | $3.00 |
| Average True Range (ATR) | 2.19 | 0.21 |
| MACD | -0.20 | -0.09 |
| Stochastic Oscillator | 31.09 | 1.18 |
The Elmet Group Co provides precision-engineered components and high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The company is organized into two business divisions, Critical Materials Components and Engineered Microwave Products, offering a platform with expertise across interconnected markets. The company operates an integrated engineering-to-production system, covering custom design, development, and processing across Critical Materials and High-Power Microwave. Its Engineered Microwave capabilities helps to deliver tailored microwave energy solutions, while its Critical Materials expertise allows to design reliable solutions for some of the demanding environments in the world.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.